Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,664 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: Cocaine Abuse, Cocaine-Related Disorders
Interventions: Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Spasticity
Interventions: Corabotase, Placebo, Dysport; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more

Conditions: Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Tinnitus
Interventions: Oxytocin, Placebo nasal spray; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Myeloma
Interventions: G-CSF, Plerixafor, Apheresis, Melphalan, Stem cell re-infusion, Basiliximab, CliniMACS CD25 microbeads and cell sorter; Drug · Procedure · Device
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Inflammatory Bowel Disease
Interventions: TD-1473, Itraconazole; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: End Stage Renal Disease, Chronic Kidney Diseases
Interventions: Berinert, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence
Interventions: Modified Atkins Diet, Absence epilepsy medications; Other · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphoma, Leukemia, Myelodysplastic Syndrome
Interventions: Fludarabine, Busulfan, Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glucose, High Blood
Interventions: Human Insulin, Finger-actuated, Metered Pump Sprayer; Biological · Device
Lead sponsor: Transdermal Delivery Solutions Corp; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Palm Beach Gardens, Florida

Conditions: Social Anxiety, Social Anxiety Disorder
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Osteo Arthritis Knee
Interventions: Ropivacaine; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Myelodysplastic Syndrome
Interventions: Vosaroxin; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma, Refractory Sarcoma
Interventions: Pazopanib, Irinotecan, Temozolomide; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Years to 30 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Oakland, California • San Francisco, California • Boston, Massachusetts

Conditions: Cirrhosis, Liver, Gastroesophageal Varices, Fontan Procedure
Interventions: Ensure Plus®, Pre-clinical validation contrast enhanced MRI, Clinical validation MRI, Pre-clinical validation contrast enhanced MRI + fasting; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma
Interventions: E7777, Fludarabine, Cyclophosphamide, Tisagenlecleucel, Axicabtagene Ciloleucel, Lisocabtagene Maraleucel Intravenous Suspension; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE)
Interventions: Fish Oil (DPA+EPA 2:1 ratio) Capsules, High Oleic Safflower Oil Capsules; Dietary Supplement
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions: AAV2-hAADC; Drug
Lead sponsor: Russell Lonser; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Adults
Interventions: Prifetrastat; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cancer
Interventions: GSK2118436, GSK1120212; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Alcohol-Related Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse, Alcohol Use Disorders
Interventions: Motivation Enhancement Therapy, Modified Behavioral Self-Control Therapy, Naltrexone, Brief Advice, Referral to specialty substance use disorder treatment; Behavioral · Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Anorexia Nervosa
Interventions: Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA); Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 15 Years to 30 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Choice, Recommendation; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 7 Years to 11 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 27
States / cities: Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more

Search by objective public record fields.

Medications for Stopping Cocaine Dependence and Preventing Relapse

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

High Dose Oxytocin Nasal Spray for Treatment of Tinnitus

Stem Cell Transplantation for Patients With Multiple Myeloma

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

Berinert (C1INH) vs Placebo for DGF/IRI

Ketogenic Diet for New-Onset Absence Epilepsy

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

Dose Response Study of Transdermal Human Insulin in Patients

Cannabidiol to Reduce Anxiety Reactivity

High Versus Low Adductor Canal Block

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes

AAV2-hAADC for Parkinson's Disease (PDCS-01)

A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes